seekingalpha.com
Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript
Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript
Curis, Inc.CRISNASDAQ
Loading
Latest News
Loading news...
prnewswire.com
Curis Provides Fourth Quarter 2025 Business Update
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.
businesswire.com
SecurityBridge Releases the Cybersecurity Resilience Index for SAP (CRIS) to Set the Standard for SAP Security Maturity Benchmarking
INGOLSTADT, Germany--(BUSINESS WIRE)--SecurityBridge, a leading provider of cybersecurity solutions for SAP, today announced the release of the Cybersecurity Resilience Index for SAP (CRIS), an industry benchmarking report that analyzes how organizations running SAP are securing their environments. The report is a timely response to global security incidents involving SAP environments that provides organizations with key actionable insights into strengths and gaps in their SAP security posture.
prnewswire.com
Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026
LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its fourth quarter 2025 financial and operating results on Thursday, March 19, 2026, at 4:00 p.m.
defenseworld.net
Head-To-Head Analysis: eXoZymes (NASDAQ:EXOZ) & Curis (NASDAQ:CRIS)
eXoZymes (NASDAQ: EXOZ - Get Free Report) and Curis (NASDAQ: CRIS - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation. Insider and Institutional Ownership 30.0% of Curis shares are
prnewswire.com
Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.
prnewswire.com
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused, high-quality institutional investors and certain insiders of the Company for a private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.
prnewswire.com
Curis Provides Updated Data from its Frontline AML Triplet Study
5 of 8 patients (62.5%) achieved Undetectable MRD (uMRD) LEXINGTON, Mass. , Dec. 9, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated clinical data from the ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104) in a poster presentation at the 67th ASH Annual Meeting (ASH).
prnewswire.com
Curis to Present at Upcoming 30th Annual SNO Meeting
LEXINGTON, Mass. , Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that Curis will report emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations and preclinical data on emavusertib in an oral presentation at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on November 19-23: November 21, 2025 – 4:30 PM ET (11:30 AM HT) Format: Poster Presentation Presenter: Dr. Christian Grommes, Memorial Sloan Kettering Cancer Center, NY, NY Title: Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination Format: Poster Presentation Presenter: Dr. Lakshmi Nayak, Dana-Farber Cancer Institute, Boston, MA Title: Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients November 22, 2025 – 4:45 PM ET (11:45 AM HT) Format: Rapid Oral Presentation Presenter: Dr. Christian Grommes, Memorial Sloan Kettering Cancer Center, NY, NY Title: Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination Format: Poster Presentation Presenter: Cecilia A.
seekingalpha.com
Curis, Inc. (CRIS) Q3 2025 Earnings Call Transcript
Curis, Inc. ( CRIS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Diantha Duvall - CFO and Principal Financial & Accounting Officer James Dentzer - President, CEO, Secretary, Treasurer & Director Ahmed Hamdy - Chief Medical Officer Conference Call Participants Sara Nik - H.C. Wainwright & Co, LLC, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Yale Jen - Laidlaw & Company (UK) Ltd.
zacks.com
Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates
Curis (CRIS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to a loss of $1.7 per share a year ago.
prnewswire.com
Curis Provides Third Quarter 2025 Business Update
Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass.
prnewswire.com
Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025
LEXINGTON, Mass. , Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m.
prnewswire.com
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LEXINGTON, Mass. , Oct. 3, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on October 1, 2025, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 84,750 shares of Curis common stock to two new employees, with a grant date of October 1, 2025 (the "Q4 2025 Inducement Grants").
seekingalpha.com
Curis, Inc. (CRIS) Presents At Cantor Global Healthcare Conference 2025 Transcript
Curis, Inc. (NASDAQ:CRIS ) Cantor Global Healthcare Conference 2025 September 5, 2025 9:45 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Conference Call Participants Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Presentation Li Wang Watsek Research Analyst Hey, everyone. Welcome to our next session with Curis.
seekingalpha.com
Curis, Inc. (CRIS) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Curis, Inc. (NASDAQ:CRIS ) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 10:00 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Presentation James Dentzer President, CEO, Secretary, Treasurer & Director Good afternoon.
prnewswire.com
Curis to Present at Upcoming Healthcare Conferences in September
LEXINGTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The Cantor Global Healthcare Conference 2025 being held September 3 – 5, 2025.
fool.com
Curis (CRIS) Q2 Loss Narrows 66%
Curis (CRIS 4.38%), a biotechnology company focused on developing targeted cancer therapies, reported its earnings for the second quarter of 2025 on August 5, 2025. Curis reported a GAAP net loss of $0.68 per share, outperforming the analyst expectation of a $1.36 GAAP loss.
seekingalpha.com
Curis, Inc. (CRIS) Q2 2025 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Ahmed M. Hamdy - Chief Medical Officer Diantha Duvall - CFO and Principal Financial & Accounting Officer James E.
zacks.com
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates
Curis (CRIS) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $1.99. This compares to a loss of $2.03 per share a year ago.